Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) CEO Yuval Cohen bought 1,695 shares of the stock in a transaction that occurred on Friday, August 11th. The stock was bought at an average cost of $6.00 per share, for a total transaction of $10,170.00. Following the completion of the purchase, the chief executive officer now directly owns 57,775 shares of the company’s stock, valued at $346,650. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) traded up 6.410% on Friday, reaching $6.225. 538,853 shares of the company’s stock were exchanged. The company has a 50 day moving average price of $6.27 and a 200 day moving average price of $7.09. Corbus Pharmaceuticals Holdings, Inc. has a one year low of $2.95 and a one year high of $10.78. The firm’s market cap is $312.62 million.

Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) last released its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.04. Corbus Pharmaceuticals Holdings had a negative return on equity of 126.20% and a negative net margin of 1,001.77%. The company had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.50 million. Analysts expect that Corbus Pharmaceuticals Holdings, Inc. will post ($0.73) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Yuval Cohen Purchases 1,695 Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) Stock” was reported by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.americanbankingnews.com/2017/08/11/yuval-cohen-purchases-1695-shares-of-corbus-pharmaceuticals-holdings-inc-crbp-stock.html.

Large investors have recently added to or reduced their stakes in the stock. Northern Trust Corp boosted its stake in Corbus Pharmaceuticals Holdings by 814.3% in the second quarter. Northern Trust Corp now owns 482,337 shares of the biopharmaceutical company’s stock worth $3,039,000 after buying an additional 429,584 shares during the period. Vanguard Group Inc. boosted its stake in Corbus Pharmaceuticals Holdings by 24.5% in the second quarter. Vanguard Group Inc. now owns 1,563,408 shares of the biopharmaceutical company’s stock worth $9,850,000 after buying an additional 307,979 shares during the period. Artal Group S.A. acquired a new stake in Corbus Pharmaceuticals Holdings during the second quarter worth approximately $1,575,000. KCG Holdings Inc. boosted its stake in Corbus Pharmaceuticals Holdings by 1,066.5% in the first quarter. KCG Holdings Inc. now owns 141,209 shares of the biopharmaceutical company’s stock worth $1,165,000 after buying an additional 129,104 shares during the period. Finally, Laurion Capital Management LP acquired a new stake in Corbus Pharmaceuticals Holdings during the first quarter worth approximately $1,015,000. Institutional investors own 28.12% of the company’s stock.

CRBP has been the topic of a number of recent analyst reports. Noble Financial reaffirmed a “buy” rating on shares of Corbus Pharmaceuticals Holdings in a research note on Friday, June 16th. Cantor Fitzgerald set a $24.00 price target on shares of Corbus Pharmaceuticals Holdings and gave the company a “buy” rating in a research report on Tuesday, June 13th. Finally, BidaskClub upgraded shares of Corbus Pharmaceuticals Holdings from a “sell” rating to a “hold” rating in a research report on Saturday, July 8th. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $20.50.

About Corbus Pharmaceuticals Holdings

Corbus Pharmaceuticals Holdings, Inc is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat rare, chronic and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment.

Insider Buying and Selling by Quarter for Corbus Pharmaceuticals Holdings (NASDAQ:CRBP)

Receive News & Ratings for Corbus Pharmaceuticals Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corbus Pharmaceuticals Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.